Neuma Develops Disinfecting Cap That Mechanically Cannot Be Used More Than Once

PALO ALTO, Calif., July 11, 2023 (Newswire.com) - Neuma Innovations^TM, creator of the original Neuma Clamp^TM that deters and detects central line abuse by IVDU (intravenous drug using) patients, today announced the development of a new disinfecting cap that prevents reuse and is tamper-evident.

"We've been working closely with infusion professionals since 2015 to design solutions to problems associated with central line blood infections. We learned that about 28% of caregivers use the same disinfecting cap more than once, which obviously compromises the caps' effectiveness. Our team set out to design a simple device that, because it can't be reattached after the first use, dramatically improves compliance," said Hal Rucker, President of Neuma Innovations. "The added benefit is that our cap also protects lines from patients who use their lines to self-inject illicit drugs."

NO CHANGES TO WORKFLOWS

The Neuma Cap^TM disinfects, approaches 100% compliance, minimizes the harmful consequences of abuse by IVDU patients, facilitates the discharge to SNF and OPAT care, and fits seamlessly into existing workflows.

"The Neuma Cap genuinely ensures the enforcement of single-use protocols while its price point remains on par with comparable alternatives," said Amy Duncan, Director of Business Development. "The ingenuity of Neuma's product lies in its indistinguishable resemblance to conventional disinfecting caps without requiring any changes in workflow. From the perspective of clinicians, the Neuma Cap is a frictionless industry disrupter for optimal patient care."

About Neuma Innovations

Neuma Innovations develops simple medical products to solve complex medical problems.

Neuma Caps and Neuma Clamps are patent-protected. Neuma, Neuma Innovations, Neuma Clamp, Neuma Central Line Protection Clamp, Neuma Cap, and Neuma Disinfecting Cap are trademarks of Neuma Innovations, LLC. All Rights Reserved. 

Copyright © 2023 Neuma Innovations LLC

Contact Information:
Hal Rucker
President
[email protected]
(650) 759-1203


Original Source: Neuma Innovations' Single-Use IV Disinfecting Cap Improves CLABSI Prevention and Deters Central Line Abuse by IVDU Patients

Enhanced Revenue Integrity offering strengthens audits, denials management, clinical documentation improvement solutions, and coder education to improve healthcare systems' financial wellness.

CARY, N.C., July 11, 2023 (Newswire.com) - AQuity Solutions, an industry-leading, tech-enabled Clinical Documentation Capture, Medical Coding, and Mid-Revenue Cycle solution supplier for healthcare provider organizations, announced the launch of its Revenue Integrity portfolio. The solutions include Claim Denial & Appeals Management, Coding Audits & Record Analysis, Claim & Edit Remediation, Clinical Documentation Improvement, and Medical Coding Education & Training services.

The highly customizable set of offerings drive revenue cycle quality and productivity, allowing hospitals, clinics, and physician practices to meet and exceed their quality benchmarks through strengthened documentation capture details, improved coding accuracy, and payer-specific claim preparations to solidify accurate revenue while ensuring compliance. AQuity's unique consultative approach helps manage risks and improve quality.

"Our Revenue Integrity solutions positively impact our client's financial success through our team of experienced consultants in over 30 specialties, including Cardiovascular Interventional Radiology (CVIR) and other complex sub-specialties," noted Susan Gatehouse, AQuity's VP of Revenue Integrity and RHIT, CCS, and ICD-10 CM/PCS AHIMA Certified Trainer. "AQuity drives revenue success by applying detailed coding, charging, billing assessments, claim auditing, denial management, and multifaceted education strategies." 

"With increased financial pressures and growing regulatory scrutiny for all provider organizations, AQuity's Revenue Integrity solutions ensure compliance and financial performance," added Kashyap Joshi, AQuity's CEO. "Our commitment to expand our Revenue Integrity offerings is in direct response to market needs and our commitment to help AQuity clients overcome their most challenging issues related to the revenue cycle." 

About AQuity

Headquartered in Cary, NC, AQuity provides solutions for 21 of the Top 25 and over half of the Top 250 Health Systems in the United States. AQuity employs over 7,500 virtual scribe and medical transcription document capture specialists, medical coders, and revenue integrity specialists in multiple specialties across the United States, India, Australia, Canada, and the U.K. With over 40 years of experience in solutions for healthcare, AQuity is recognized year after year by KLAS and Black Book as a leading vendor in multiple disciplines. AQuity is privately held. https://aquitysolutions.com. 

Contact Information:
Dale Kivi
Senior Director of Communications
[email protected]
804.339.9017


Original Source: AQuity Broadens Its Portfolio With Launch of Revenue Integrity Solutions

The merger will combine URA's exclusive technology and expertise with Diamond Institute's best fertility specialists to create one of the strongest networks of fertility clinics in northern New Jersey and New York.

HASBROUCK HEIGHTS, N.J., July 11, 2023 (Newswire.com) - University Reproductive Associates (URA) and Diamond Institute today announced a merger that will create one of the most technologically advanced networks of fertility clinics in northern New Jersey and New York, as well as the most personalized. Both URA and Diamond Institute have built their successes on excellence in care, from initial evaluation to guidance on financial assistance. That care will now be available at six offices in six counties. New Jersey offices: Hasbrouck Heights in Bergen County, Wayne in Passaic County, Millburn in Essex County, Denville in Morris County and Hoboken in Hudson County. New York office: Goshen in Orange County.

According to Peter McGovern, M.D., a founding physician at URA, the merger will result in a new level of fertility care and solutions as more treatment options will be available, delivered with the one-on-one, personal care for which both organizations are known among their patients. URA is already the first and only fertility clinic network in New Jersey to offer the LifeAire in-duct air purification system, leading to a 15%-20% higher chance of successful implantation and pregnancy. URA is also the only network of fertility clinics in New Jersey to offer robotic surgery using the da Vinci^® Surgical System. 

From Diamond Institute, the merger will bring to URA two leading fertility specialists in New Jersey, Dr. Matan Yemini and Dr. Ndidiamaka Onwubalili. Dr. Yemeni brings 30 years of experience focusing interest, practice and research on the spectrum of issues associated with reproductive endocrinology and infertility treatment. Dr. Yemeni is bilingual, also speaking Hebrew. Dr. Onwubalili, aka "Dr. O," is board-certified in Obstetrics and Gynecology and Reproductive Endocrinology. She is a Fellow of the American Congress of Obstetricians, and her clinical and research focus includes polycystic ovarian syndrome, fertility preservation, uterine fibroids, and minimally invasive surgery.

"There's no doubt that URA provides families-to-be with higher chances than most fertility clinics through technology. Combined with the warm, personal care that's already our standard with each and every couple, I think the merger will create something even better than the sum of its parts," Dr. Onwubalili said.

Contact Information:
Leonard Schwartz
Practice Manager
[email protected]
201-288-6330


Original Source: University Reproductive Associates Merges With Diamond Institute to Create a Network of Fertility Clinics in Both Northern New Jersey and New York

Specialty pharmaceutical research company celebrates the launch of a new service offering and with it, a brand refresh.

ALBANY, N.Y., July 11, 2023 (Newswire.com) - Glauconix Biosciences, Inc. is now Humonix Biosciences, Inc.

What began as a specialization in glaucoma therapeutics has become a launchpad for developing new fibrotic and vascular 3D human tissue models. The company is proud to announce a new retinal vascular dysfunction 3D model proven to express key physiological and biological characteristics. The new model can help along all aspects of the drug development process and expedite drug development by utilizing 3D human tissue, which has greater translatability and quicker turnaround times than other more traditional pre-clinical testing methods. 

Now that the company has expanded beyond glaucoma and successfully proven that the platform technology can support various cell types, the company has changed its name to Humonix Biosciences. This move is reflective of a larger breadth of service offerings and a vision to expand the 3D human tissue systems to address other diseases in the body.

"This is a very exciting time for us as we move closer to our vision to make all fibrotic and vascular diseases treatable. We are making good on our commitment to our customers to relentlessly innovate and create new opportunities for breakthrough therapies to succeed." - Kimberly Southern, Chief Executive Officer, Humonix

"It's a transformational time for Humonix as they expand their industry-leading platform technology to address the significant unmet need in the marketplace for validated fibrotic and vascular 3D tissue models. I'm excited to continue supporting the company and looking forward to seeing what comes next!" - Robert Dempsey, Chief Executive Officer, President, AsclepiX Therapeutics, Inc and Humonix Board Member

Additional information:

• Learn more about our new Retinal Vascular Dysfunction Model: https://www.humonixbio.com/rvdm
• Read our poster about our new Retinal Vascular Dysfunction model from the Association for Research in Vision and Ophthalmology here: https://www.humonixbio.com/presentations

Contact Information:
George Torrejon
Senior Director
[email protected]
(631) 487-5553


Original Source: Glauconix is Now Humonix

Smile's new addition to its privacy certification is the best of both worlds—compliance and data protection.

TORONTO, July 11, 2023 (Newswire.com) - Smile Digital Health (Smile), a leading FHIR® health data fabric and exchange solutions provider, announced today that it has successfully implemented ISO 27018:2019, an international guideline focused on safeguarding personally identifiable information (PII) in cloud computing. 

ISO 27018 is entirely voluntary; however, Smile chose to extend its current certification of ISO 27001 with ISO 27018 to ensure its privacy information management system meets the most comprehensive guidelines when it comes to collecting, processing, storing, sharing and destroying PII and protected health information (PHI) data in the Cloud. Although the focus of ISO 27018 is data protection, it also offers guidelines for the General Data Protection Regulation (GDPR), the California Consumer Privacy Act (CCPA) and other regulatory compliance. Along with PII handling, ISO 27018 provides guidelines for third-party management for subcontractors and security incident management.

ISO 27018 certification is particularly relevant for customers of Smile's Cloud-based Managed Services offering. Smile Managed Services is an end-to-end service package encompassing FHIR-based implementation, maintenance, security and support for cloud or hybrid-deployed Health Data Fabric (HDF) solutions. Managed Services customers can trust that their data is safeguarded and won't be used for any purposes other than those that they give consent for based on the ISO 27018 controls, objectives and guidelines.

"ISO 27018 ensures the data our Managed Services customers store, share and process in the Cloud is handled based on the highest level of privacy standards," said George Rollins, President, Smile Digital Health. "I'm proud that we can offer solutions and support that provide the security our customers look to us for. Our privacy information management system and all that our team has been able to accomplish in terms of certifications is truly impressive."

"It's important for us as we continue to grow our product and service offerings to ensure we are always operating with the highest standards when it comes to security and privacy. Our Managed Services solution made implementing ISO 27018 the obvious next step for us in terms of PII protection in the Cloud," said Luis de Barros, Chief Privacy and Security Officer, Smile Digital Health.

About Smile Digital Health

Smile Digital Health is a health information technology company focused on delivering better global health through open standards. Our enterprise-grade, open framework data fabric and integration platform fuels healthcare's digital transformation and accelerates value creation across all patient journeys at scale. Powered by our HL7® FHIR® standard-based clinical data repository (#SmileInside), our platform enables collaboration and allows organizations to ingest, transform, store, enrich, analyze, aggregate, and meaningfully share health information to power digital transformation. We prepare healthcare providers, payers, researchers, and life sciences organizations for a connected future beyond legacy systems, adding new value through the intelligent use of information, and ultimately delivering better patient outcomes. For more information, visit SmileDigitalHealth.com. 

Contact Information:
Victoria Valladolid
Director of Marketing, Smile Digital Health
[email protected]
(877) 537-3343 x 728


Original Source: Smile Digital Health Achieves ISO 27018 Certification